120077-69-2

Basic information

• Product Name: 4-BROMO-3-CHLORO-BENZALDEHYDE
• Synonyms: 4-BROMO-3-CHLORO-BENZALDEHYDE;4 - broMine - 3 - chlorobenzene forMaldehyde;4-BrMo-3-chlorobenzaldehyde
• CAS NO: 120077-69-2
• Molecular Formula: C₇H₄BrClO
• Molecular Weight: 219.46
• Mol File: 120077-69-2.mol

Chemical Properties

• Melting Point: 52 °C
• Boiling Point: 281.255 °C at 760 mmHg
• Flash Point: 123.899 °C
• Appearance: /
• Density: 1.698 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-BROMO-3-CHLORO-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-CHLORO-BENZALDEHYDE(120077-69-2)
• EPA Substance Registry System: 4-BROMO-3-CHLORO-BENZALDEHYDE(120077-69-2)

Safety Data

• Hazardous Substances Data: 120077-69-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-CHLORO-BENZALDEHYDE is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving existing ones. Its unique chemical structure allows for the creation of diverse medicinal compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-3-CHLORO-BENZALDEHYDE is utilized as a building block in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds helps enhance crop protection and yield, ensuring sustainable agricultural practices.
Used in Plant Growth Regulation:
4-BROMO-3-CHLORO-BENZALDEHYDE plays a role in the synthesis of plant growth regulators, which are essential for controlling and optimizing plant growth and development. These regulators can be used to improve crop quality, increase resistance to diseases, and enhance overall agricultural productivity.
Used in Fine Chemicals Synthesis:
4-BROMO-3-CHLORO-BENZALDEHYDE is employed as a versatile reagent in the synthesis of fine chemicals, which are high-purity specialty chemicals used in various applications, such as fragrances, dyes, and flavorings. Its unique properties enable the production of a wide range of high-quality fine chemicals.
Used in Research and Development:
In the realm of research and development, 4-BROMO-3-CHLORO-BENZALDEHYDE is an important chemical reagent for exploring new chemical reactions, synthesizing novel compounds, and advancing scientific knowledge. Its use in research facilitates the discovery of innovative applications and technologies across various fields.

InChI:InChI=1/C7H4BrClO/c8-6-2-1-5(4-10)3-7(6)9/h1-4H

Upstream product

• 163596-75-6 4-bromo-3-nitrobenzaldehyde 
• 1122-91-4 4-bromo-benzaldehyde 
• 359867-42-8 3-amino-4-bromobenzaldehyde 
• 79-37-8 oxalyl dichloride 
• 120077-68-1 (4-bromo-3-chlorophenyl)methanol 
• 67-68-5 dimethyl sulfoxide 
• 1235711-34-8 4-bromo-3-chloro-N-methoxy-N-methyl-benzamide 
• 57418-97-0 4‐bromo‐3‐chlorobenzonitrile 
• 21803-75-8 4-amino-3-chlorobenzonitrile 
• 25118-59-6 4-bromo-3-chlorobenzoic acid 

Downstream Products

• 25118-59-6 4-bromo-3-chlorobenzoic acid 
• 927670-47-1 4-(4-bromo-3-chloro-phenyl)-2-butyl-5-oxo-4,5,6,8-tetrahydro-1H-pyrano[3,4-b]pyridine-3-carboxylic acid ethyl ester 
• 1063712-33-3 2-(4-bromo-3-chlorophenyl)-1,3-dioxolane 
• 1253045-34-9 C₁₂H₁₄BrClO 
• 1261878-70-9 ethyl 3-(4-bromo-3-chlorophenyl)propanoate 
• 1308280-00-3 ethyl 3-[4-(3'-(1-adamantyl)-4'-benzyloxyphenyl)-3-chlorophenyl]propanoate 
• 1308280-06-9 ethyl 3-[4-(3'-(1-adamantyl)-4'-hydroxy)-3-chlorophenyl]propanoate 
• 1308280-12-7 3-[4-(3'-(1-adamantyl)-4'-hydroxy)-3-chlorophenyl]propionic acid 
• 1318805-50-3 1-(4-bromo-3-chlorophenyl)but-3-en-1-ol 
• 1338326-95-6 N-(4-bromo-3-chlorobenzyl)-N-methylmethanesulfonamide 
• 1338326-96-7 1-(4-bromo-3-chlorophenyl)-N-methylmethanamine 
• 1338326-99-0 N-(4-bromo-3-chlorobenzyl)-N-methylacetamide 
• 1261614-16-7 1-bromo-2-chloro-4-(difluoromethyl)benzene 
• 1338327-10-8 tert-butyl 3-((3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)(methyl)amino)-3-oxopropylcarbamate 

Relevant articles and documents

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein

Chemical subtleties in small-molecule modulation of peptide receptor function: The case of CXCR3 biaryl-type ligands

The G protein-coupled chemokine receptor CXCR3 plays a role in numerous inflammatory events. The endogenous ligands for the chemokine receptors are peptides, but in this study we disclose small-molecule ligands that are able to activate CXCR3. A class of biaryl-type compounds that is assembled by convenient synthetic routes is described as a new class of CXCR3 agonists. Intriguingly, structure-activity relationship and structure-function relationship studies reveal that subtle chemical modifications on the outer aryl ring (e.g., either the size or position of a halogen atom) result in a full spectrum of agonist efficacies on CXCR3. Quantum mechanics calculations and nuclear Overhauser effect spectroscopy NMR studies suggest that the biaryl dihedral angle and the electronic nature of ortho-substituents play an important role in determining agonist efficacies. Compounds 38 (VUF11222) and 39 (VUF11418) are the first reported nonpeptidomimetic agonists on CXCR3, rendering them highly useful chemical tools for detailed assessment of CXCR3 activation as well as for studying downstream CXCR3 signaling.

Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4- hydroxyphenyl]-3-chlorocinnamic acid

(E)-4-[3'-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell cycle arrest and apoptosis of cancer cells. Because its pharmacologic properties-solubility, bioavailability, and toxicity-required improvement for translation, s

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications

The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.

Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of Src homology 2 domain-containing protein tyrosine phosphatase-2 activity

(E)-4-[3-(1-Adamantyl)-4′-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells. Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP). Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression. 3-Cl-AHPC analogues having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis. Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity. Docking of 3-Cl-AHPC and its analogues to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity. Inhibitory activity against Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp-2) was also assessed. The most active Shp-2 inhibitor was found to be the 3′-(3,3-dimethylbutynyl) analogue of 3-Cl-AHPC.

IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.